Title An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
Authors Wang, Dongyuan
Li, Zigang
Liu, Yihui
Affiliation Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pharm, 1277 Jie Fang Rd, Wuhan 430022, Hubei, Peoples R China
Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, State Key Lab Chem Oncogen, Lishui Rd, Shenzhen, Peoples R China
Pingshan Translat Med Ctr, Shenzhen Bay Lab, Shenzhen, Peoples R China
Keywords ACUTE-RESPIRATORY-SYNDROME
CORONAVIRUS
RIBAVIRIN
CHLOROQUINE
EFFICACY
SARS
INTERFERON-ALPHA-2B
REPLICATION
INHIBITION
REMDESIVIR
Issue Date Oct-2020
Publisher JOURNAL OF INFECTION AND PUBLIC HEALTH
Abstract Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease-19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event. No specific antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The treatments for COVID-19 are mainly based on the experiences of similar virus such SARS-CoV, MERS-CoV, HIV and influenza viruses. Scientists have taken great efforts to investigate the effective methods for the treatment of COVID-19. Up to now, there are over 1000 clinical studies for COVID-19 all over the world. In this article, we reviewed the current options for COVID-19 therapy including small molecules such as Remdesivir, Favipiravir, Lopinavir/Ritonavir etc, peptide inhibitors of ACE2, Traditional Chinese Medicines and Biologics such as SARS-CoV-2-specific neutralizing antibodies, mesenchymal stem cells and vaccines etc. Meanwhile, we systematically reviewed their clinical safety, clinical applications and progress of antiviral researches. The therapeutic effect of these antiviral drugs is summarized and compared, hoping to provide some ideas for clinical options of COVID-19 treatment and also provide experiences for the life-threatening virus diseases in the future. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
URI http://hdl.handle.net/20.500.11897/592637
ISSN 1876-0341
DOI 10.1016/j.jiph.2020.07.004
Indexed SCI(E)
Appears in Collections: 深圳研究生院待认领

Files in This Work
There are no files associated with this item.

Web of Science®


0

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.